Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy

2021159 citationsJournal Articlegold Open Access

Authors

Peter Rossing · Steno Diabetes Centers

Gerasimos Filippatos · National and Kapodistrian University of Athens

Rajiv Agarwal · Indiana University – Purdue University Indianapolis

Stefan D. Anker · German Centre for Cardiovascular Research

Bertram Pitt · University of Michigan

Luís M. Ruilope · Universidad Europea

Juliana C.N. Chan

Abstract

UACR improvement was observed with finerenone in patients with CKD and T2D already receiving SGLT-2is at baseline, and benefits on kidney and cardiovascular outcomes appear consistent irrespective of use of SGLT-2i.

Topics & Keywords

Diabetes Treatment and Management Diet and metabolism studies Hormonal Regulation and Hypertension

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Kidney International Reports

Volume 7, Issue 1, pp. 36-45

DOI: 10.1016/j.ekir.2021.10.008

Field-Weighted Citation Impact: 18.34